Immix Biopharma Reports CAR-T NXC-201 To Expansion Cohort Dose Level In U.S. AL Amyloidosis Trial NEXICART-2
Portfolio Pulse from Benzinga Newsdesk
Immix Biopharma has advanced its CAR-T therapy, NXC-201, to a higher dose level in its U.S. trial for AL Amyloidosis. The trial, NEXICART-2, is now dosing at 450 million CAR+T cells, following successful results at a lower dose. NXC-201 is the only one-time CAR-T treatment for this condition in U.S. trials.
October 02, 2024 | 1:33 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Immix Biopharma's NXC-201 CAR-T therapy has progressed to a higher dose level in its U.S. trial for AL Amyloidosis, showing promising results. This advancement could enhance the company's position in the biotech sector.
The successful progression to a higher dose level in the NEXICART-2 trial indicates positive clinical outcomes, which could lead to increased investor confidence and potential stock price appreciation for Immix Biopharma.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100